These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 1494904

  • 21. Iron-binding characteristics of neuromelanin of the human substantia nigra.
    Double KL, Gerlach M, Schünemann V, Trautwein AX, Zecca L, Gallorini M, Youdim MB, Riederer P, Ben-Shachar D.
    Biochem Pharmacol; 2003 Aug 01; 66(3):489-94. PubMed ID: 12907248
    [Abstract] [Full Text] [Related]

  • 22. Individual dopaminergic neurons show raised iron levels in Parkinson disease.
    Oakley AE, Collingwood JF, Dobson J, Love G, Perrott HR, Edwardson JA, Elstner M, Morris CM.
    Neurology; 2007 May 22; 68(21):1820-5. PubMed ID: 17515544
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. XANES spectroscopy of a single neuron from a patient with Parkinson's disease.
    Yoshida S, Ektessabi A, Fujisawa S.
    J Synchrotron Radiat; 2001 Mar 01; 8(Pt 2):998-1000. PubMed ID: 11513007
    [Abstract] [Full Text] [Related]

  • 25. Residual substantia nigra neuromelanin in Parkinson's disease is cross-linked to alpha-synuclein.
    Fasano M, Giraudo S, Coha S, Bergamasco B, Lopiano L.
    Neurochem Int; 2003 Jun 01; 42(7):603-6. PubMed ID: 12590943
    [Abstract] [Full Text] [Related]

  • 26. Neuromelanin-bound ferric iron as an experimental model of dopaminergic neurodegeneration in Parkinson's disease.
    Gerlach M, Riederer P, Double KL.
    Parkinsonism Relat Disord; 2008 Jun 01; 14 Suppl 2():S185-8. PubMed ID: 18585086
    [Abstract] [Full Text] [Related]

  • 27. Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta.
    Langley J, Huddleston DE, Sedlacik J, Boelmans K, Hu XP.
    Mov Disord; 2017 Mar 01; 32(3):441-449. PubMed ID: 28004859
    [Abstract] [Full Text] [Related]

  • 28. Melanin and neuromelanin binding of drugs and chemicals: toxicological implications.
    Karlsson O, Lindquist NG.
    Arch Toxicol; 2016 Aug 01; 90(8):1883-91. PubMed ID: 27311820
    [Abstract] [Full Text] [Related]

  • 29. Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson's disease.
    Ben-Shachar D, Eshel G, Riederer P, Youdim MB.
    Ann Neurol; 1992 Aug 01; 32 Suppl():S105-10. PubMed ID: 1510367
    [Abstract] [Full Text] [Related]

  • 30. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?
    Kastner A, Hirsch EC, Lejeune O, Javoy-Agid F, Rascol O, Agid Y.
    J Neurochem; 1992 Sep 01; 59(3):1080-9. PubMed ID: 1494900
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Evidence for a glycidic-lipidic matrix in human neuromelanin, potentially responsible for the enhanced iron sequestering ability of substantia nigra.
    Aime S, Fasano M, Bergamasco B, Lopiano L, Valente G.
    J Neurochem; 1994 Jan 01; 62(1):369-71. PubMed ID: 8263538
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Effects of L-cysteine on the oxidation chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson's disease.
    Zhang F, Dryhurst G.
    J Med Chem; 1994 Apr 15; 37(8):1084-98. PubMed ID: 7909337
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Iron and other metals in neuromelanin, substantia nigra, and putamen of human brain.
    Zecca L, Pietra R, Goj C, Mecacci C, Radice D, Sabbioni E.
    J Neurochem; 1994 Mar 15; 62(3):1097-101. PubMed ID: 8113797
    [Abstract] [Full Text] [Related]

  • 38. In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage.
    Zecca L, Berg D, Arzberger T, Ruprecht P, Rausch WD, Musicco M, Tampellini D, Riederer P, Gerlach M, Becker G.
    Mov Disord; 2005 Oct 15; 20(10):1278-85. PubMed ID: 15986424
    [Abstract] [Full Text] [Related]

  • 39. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity.
    D'Amato RJ, Alexander GM, Schwartzman RJ, Kitt CA, Price DL, Snyder SH.
    Nature; 2005 Oct 15; 327(6120):324-6. PubMed ID: 2884568
    [Abstract] [Full Text] [Related]

  • 40. Influence of neuromelanin on oxidative pathways within the human substantia nigra.
    Double KL, Ben-Shachar D, Youdim MB, Zecca L, Riederer P, Gerlach M.
    Neurotoxicol Teratol; 2002 Oct 15; 24(5):621-8. PubMed ID: 12200193
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.